What happened
SUMMIT evaluates tirzepatide for reverse atrial and right-heart remodeling in obesity-related HFpEF.
“It turned out that paracardiac fat fell markedly in the treated group, whereas it didn't change in the placebo group. And as that reduces, there's a reduction in circulating cytokines, those molecules that are released from the paracardiac fat that do damage. So basically, everything surrounding obesity-related heart failure with preserved ejection fraction was improved with active therapy.”
Quoted in News Coverage ↗Why the trial, tables, limitations, PICO, abstract, media & sources
Expert reaction
AHA Scientific Sessions 2026
Expert labels are toward SUMMIT Remodeling's result, from named public quotes (n=1). As of Nov 3, 2026.
Tirzepatide and Reverse Remodeling of the Left Atrium and Right Heart in Obesity-Related Heart Failure With Preserved Ejection Fraction (SUMMIT)
Tirzepatide and Reverse Remodeling of the Left Atrium and Right Heart in Obesity-Related Heart Failure With Preserved Ejection Fraction (SUMMIT). Presented by Christopher Kramer (University of Virginia Health, Charlottesville, USA). Session: FS.07. Late-breaking trial at AHA Scientific Sessions 2026. Results pending.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Kramer et al. (2026) studied this question. Tirzepatide is being evaluated for reverse remodeling of the left atrium and right heart in obesity-related HFpEF in the SUMMIT trial, with results pending.